SWP
VTVT icon

Stratos Wealth Partners’s vTv Therapeutics VTVT Stock Holding History

Stratos Wealth Partners’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1
Closed – – 2476
2018
Q3 		$0 Buy
+1
New +$47 ﹤0.01% 3052
2018
Q2 		– Sell
-1
Closed – – 2563
2018
Q1 		$0 Hold
1
– – ﹤0.01% 3234
2017
Q4 		$0 Buy
+1
New +$224 ﹤0.01% 2837

Other funds holding VTVT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Stratos Wealth Partners's VTVT Position: Q4 2018 in Review

Stratos Wealth Partners sold out of vTv Therapeutics (VTVT) in Q4 2018, closing a stake of 1 share.

Stratos Wealth Partners first reported a position in VTVT in Q4 2017 and held it in 3 quarters. The position peaked at $0 in Q3 2018. 17 funds tracked by Wall St. Rank hold VTVT as of Q4 2018.

  • Stratos Wealth Partners reported no remaining vTv Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Stratos Wealth Partners sold 1 vTv Therapeutics share in Q4 2018.
  • Stratos Wealth Partners first reported a position in vTv Therapeutics in Q4 2017 and held it in 3 quarters.
  • Stratos Wealth Partners's vTv Therapeutics position peaked at $0 in Q3 2018.
  • 17 funds tracked by Wall St. Rank held vTv Therapeutics as of Q4 2018.

Based on Stratos Wealth Partners's 13F filing for Q4 2018, filed 8 Feb 2019.